Dr. Amber Cai China

Geneception is an innovation-driven biopharmaceutical company focusing on gene and cell therapy medicines.

Website:
N/A
Company Size (Fulltime employees)
Please specify your partnering goal
Gene therapy & cell therapy program
Headquartner in China
Biotech/Pharma Category
Geneception  Inc.
CEO 
Functionality

Dr Cynthia Cai China

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.
Dr Cynthia Cai
Viva Bioinnovator
LinkedIn logo Venture Partner 

Mr. Jeff Cao China

Our vision is: Curing cancer, pushing science to its limits and contributing to safe medical devices around the world!

As a medical device software specialist, we help MedTech startups get to their next milestone faster and safer. We have 20 years of experience and 220 in-house engineers to back you up and get you to the finish line - getting your device to market.
see less
Company Size (Fulltime employees)
Year of foundation
2019
Please specify your partnering goal
TO EMPOWER HIGH quartile medical startups
Headquartner in China
Medtech Category
ARROWFAST
VP CHINA 
Functionality

Eric Chang China

Kaitai is a biotech venture fund with about 40 biotech portfolio companies. Kaitai's fund size is about 7 billions dollars. They are positively looking for cutting edge technologies.
Partnering Objectives
Headquartner in China
Kaitai Capital
Executive Director 

Nick Cheh China

FEBICO (Far East Bio-Tec. Co., Ltd.) was established in 1976. We have three main business segments: New Drug Development, Diagnostic Reagents, and Dietary Supplement .
We develop an anti-virus platform, FEM, to develop potential drug candidates.
We focus on developments of botanical drugs and biologics to resolve the unmet medical needs such as inflammation diseases (lung injury, liver inflammation, liver fibrosis), hepatitis B, and herpes.
Website:
www.febico.com
Company Size (Fulltime employees)
Year of foundation
1990
Partnering Objectives
Headquartner in China
Biotech/Pharma Asset Stage
Far East Bio-Tec. Co., Ltd
Director of BD 
Functionality

Denise Chen China

GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ¥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Website:
www.szgig.com
Company Size (Fulltime employees)
Please specify your partnering goal
potential investing targets and collaborations
Headquartner in China
Medtech Development Stage
GIG
Partner 
Functionality

Paul Chen China

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global Phase II trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Looking to in-license / out-license
Headquartner in China
Biotech/Pharma Asset Stage
Reistone Biopharma
Chief of Staff 
Functionality

Mr Jim Chen China

Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion.  It's a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas.   Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.

For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases.

Website:
www.chasesun.cn
Company Size (Fulltime employees)
Year of foundation
1996
Headquartner in China
Biotech/Pharma Asset Stage
Tianjin chasesun pharmaceutical co ltd
Investment Manager 
Functionality

Mr. Mark Chen China

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Company Size (Fulltime employees)
Year of foundation
2009
Partnering Objectives
Please specify your partnering goal
Licensing-in
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Kintor Pharmaceuticals
BD Director 
Functionality